- Researchers investigated whether digitalis glycosides improve clinical outcomes for patients with heart failure with mildly reduced or reduced ejection fraction.
- This meta-analysis synthesized data from three large randomized controlled trials involving 9,013 patients with a mean age of 64.5 years.
- Digitalis reduced worsening heart failure events (HR 0.75; 95% CI, 0.69-0.81; P < .001) but did not impact cardiovascular mortality.
- The authors concluded that digitalis glycosides significantly lower the risk of hospitalization or worsening symptoms regardless of background therapy.
- Clinicians may consider digitalis as an adjunctive therapy to specifically target and reduce the frequency of worsening heart failure episodes.
Reassessing the Clinical Utility of Digitalis in Modern Heart Failure Management
Digitalis glycosides remain a long-standing component of the cardiovascular pharmacopeia, though their role has diminished as neurohormonal therapies have become the standard of care [1]. While historical data indicated improvements in exercise capacity, subsequent observational analyses raised concerns regarding increased mortality, particularly in patients with comorbid atrial fibrillation where a 27 percent to 29 percent increase in the risk of death has been reported [2, 3]. In contrast, meta-analyses of randomized controlled trials involving 9,013 patients have demonstrated a neutral effect on all-cause mortality (Hazard Ratio 0.97; 95 percent Confidence Interval, 0.90 to 1.04) while showing a significant reduction in hospital admissions for worsening heart failure [4, 5]. This discrepancy creates a clinical challenge for physicians managing patients who remain symptomatic despite receiving optimized guideline-directed medical therapy (the combination of evidence-based treatments including beta-blockers, renin-angiotensin system inhibitors, and mineralocorticoid receptor antagonists). To clarify this issue, recent evidence evaluates whether these agents provide incremental benefit when integrated into modern treatment protocols for heart failure with reduced ejection fraction (a clinical diagnosis where the left ventricular ejection fraction is 40 percent or less).
Rigorous Selection of Large-Scale Randomized Evidence
To evaluate the impact of digitalis glycosides on clinical outcomes, researchers conducted a systematic review and meta-analysis focusing on patients with heart failure with mildly reduced ejection fraction (HFmrEF, defined as a left ventricular ejection fraction between 41 percent and 49 percent) or heart failure with reduced ejection fraction (HFrEF, defined as an ejection fraction of 40 percent or less). The investigators searched PubMed from its inception through March 1, 2026, utilizing medical subject headings (standardized descriptors used for indexing medical articles) and specific keywords related to digitalis glycosides and heart failure. The selection process was intentionally restrictive, including only placebo-controlled randomized clinical trials that enrolled more than 1000 patients and were published in the English language. This high threshold for study size was designed to minimize the influence of small-study effects and provide sufficient statistical power for the analysis. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guideline (a standardized framework for ensuring transparent and complete reporting of systematic reviews), two independent reviewers extracted the data. To maintain high internal validity, the researchers assessed the risk of bias using the Cochrane Risk of Bias tool (version 2), which evaluates potential flaws in study design, conduct, and reporting. Ultimately, three large-scale studies met these stringent inclusion criteria, providing a combined cohort of 9,013 patients with HFmrEF or HFrEF. By focusing exclusively on large, placebo-controlled trials, the meta-analysis aimed to clarify the role of digitalis in a population that often requires additional therapeutic options when standard guideline-directed medical therapy is insufficient to prevent clinical deterioration.
Significant Reductions in Worsening Heart Failure Events
The researchers utilized a fixed-effects model (a statistical method that assumes the treatment effect is consistent across all included studies) to estimate the hazard ratios (HRs) with 95% confidence intervals (CIs). The primary end point was defined as the composite of time to cardiovascular death or first worsening heart failure event. In the final analysis, this composite outcome occurred in 1852 of 4510 patients (41%) in the digitalis glycoside group compared to 2037 of 4503 patients (45%) in the placebo group. This difference represented a statistically significant reduction in risk, with a hazard ratio of 0.85 (95% CI, 0.80-0.90; P < .001). When examining the individual components of the primary endpoint, the benefit was driven primarily by a reduction in clinical deterioration rather than a change in mortality rates. A first worsening heart failure event occurred in 1183 (26%) patients in the digitalis glycoside group versus 1474 (33%) patients in the placebo group. This 7% absolute reduction in events corresponded to a hazard ratio for first worsening heart failure event of 0.75 (95% CI, 0.69-0.81; P < .001). For practicing clinicians, these data suggest that while digitalis glycosides do not alter the underlying survival trajectory, they significantly decrease the frequency of acute exacerbations and hospitalizations, offering a valuable tool for keeping vulnerable patients out of the inpatient ward.
Neutral Impact on Cardiovascular and All-Cause Mortality
To provide a comprehensive assessment of safety and efficacy, the researchers evaluated secondary outcomes that included the individual components of the composite outcome and the time to all-cause death. These mortality data are particularly relevant for clinicians who may have concerns regarding the historical safety profile of digitalis glycosides in diverse patient populations. The analysis revealed that cardiovascular mortality was identical between the two study arms, with 1224 cardiovascular deaths occurring in the digitalis glycoside group and 1224 in the placebo group, representing 27% of participants in each cohort. The resulting hazard ratio for cardiovascular death was 0.99 (95% CI, 0.92-1.07; P = .81), indicating that the therapy does not influence the risk of death from heart failure or other cardiovascular causes. The findings regarding all-cause mortality further support a neutral effect on survival. There were 1466 all-cause deaths in the digitalis glycoside group compared to 1497 in the placebo group, which corresponds to 32% and 33% of the respective populations. This small numerical difference was not statistically significant, as evidenced by a hazard ratio for all-cause death of 0.97 (95% CI, 0.90-1.04; P = .41). Collectively, these data demonstrate that while digitalis glycosides effectively reduce the frequency of worsening heart failure events, they do not alter the overall mortality trajectory for patients with heart failure with mildly reduced or reduced ejection fraction. For the practicing physician, these results provide reassurance that digitalis can be utilized to improve clinical stability without increasing the risk of fatal outcomes.
Consistency Across Patient Subgroups and Background Therapies
The meta-analysis included a diverse clinical population that reflects the typical demographic profile of patients managed in cardiology practices. The study population had a weighted mean age of 64.5 years (weighted standard deviation, 11.2 years), providing data relevant to both middle-aged and elderly patients. In terms of sex distribution, the cohort was 22% female and 78% male. This demographic breadth ensures that the observed benefits of digitalis glycosides are applicable across a wide range of patient profiles encountered in daily clinical rotations. A critical finding for clinicians is the high degree of stability in the treatment effect across different therapeutic contexts. The researchers reported that there was no statistically significant heterogeneity by trial, type of digitalis glycoside treatment, or extent of background heart failure therapy. This lack of heterogeneity (a statistical measure indicating that the results were consistent across different studies and did not vary by chance) suggests that the reduction in worsening heart failure events is a reliable outcome. Furthermore, there was no statistically significant interaction with the extent of heart failure background therapy or type of digitalis glycosides treatment, meaning the medication remained effective whether patients were on older regimens or more intensive modern heart failure therapies. For the practicing physician, these data indicate that digitalis serves as a consistent adjunct to reduce morbidity, regardless of the specific glycoside chosen or the complexity of the patient's existing medication list.
References
1. Sciatti E, D'Elia E, Gori M, et al. The comeback of digitalis (digitoxin): the DIGIT-HF trial. European Heart Journal, Supplement. 2026. doi:10.1093/eurheartjsupp/suag031
2. Qureshi W, O’Neal WT, Soliman EZ, Al‐Mallah MH. Systematic review and meta-analysis of mortality and digoxin use in atrial fibrillation. Cardiology Journal. 2016. doi:10.5603/cj.a2016.0016
3. Vámos M, Erath JW, Hohnloser SH. Digoxin-associated mortality: a systematic review and meta-analysis of the literature. European Heart Journal. 2015. doi:10.1093/eurheartj/ehv143
4. Ziff OJ, Lane DA, Samra M, et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ. 2015. doi:10.1136/bmj.h4451
5. Damman K, Veldhuisen DJV, Bauersachs J, et al. Efficacy and Safety of Digitalis Glycosides in Heart Failure: A Meta-Analysis.. JAMA. 2026. doi:10.1001/jama.2026.7886